Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

TROV RSS Feed
Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/2/2019 3:30:36 PM - Followers: 71 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
USA
 
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
http://trovagene.com/
 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
 
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.

Highlights:

Trovagene Closes Acquisition of CLIA Laboratory Assets
 
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
 
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
 
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
 
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board


Targeted $40 Billion market space:
TROV market space



TROV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Statement of Changes in Beneficial Ownership (4) 10/03/2019 04:17:14 PM
TROV News: Current Report Filing (8-k) 10/02/2019 10:34:07 AM
TROV News: Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Trip... 10/02/2019 08:15:00 AM
TROV News: Current Report Filing (8-k) 10/01/2019 11:15:41 AM
TROV News: Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mC... 10/01/2019 08:15:00 AM
PostSubject
#1467   Data Presented at ESMO Provides Rationale for Clinical abracky 10/02/19 03:30:36 PM
#1466   looking better today, big bids on huge red Derek ops 10/02/19 12:51:49 PM
#1465   Just added back 1.34 Derek ops 10/01/19 10:03:26 AM
#1464   * * $TROV Video Chart 09-30-2019 * * ClayTrader 09/30/19 05:50:17 PM
#1463   News: $TROV Positive Data from Trovagene Phase 1b/2 whytestocks 09/30/19 10:10:22 AM
#1462   Good news today CyrusDaVirus 09/30/19 10:05:13 AM
#1461   Good luck. I got beat up on the MegaDeath 09/19/19 01:30:22 PM
#1460   This stock is trading crazy cheap. Or maybe Derek ops 09/19/19 01:08:47 PM
#1459   Trovagene Announces Successful Completion of Phase 1b Trial MegaDeath 09/19/19 09:02:23 AM
#1458   added more 1.81 and 1.76 Derek ops 09/18/19 02:52:32 PM
#1457   added 1.87 in AH, good volume hit as Derek ops 09/13/19 10:01:46 PM
#1456   Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Source: Edgar (US abracky 09/12/19 05:32:53 PM
#1455   Current Report Filing (8-k) Source: Edgar (US Regulatory)   UNITED STATES SE abracky 09/03/19 02:15:56 PM
#1454   Trovagene to Present at the H.C. Wainwright 21st abracky 09/03/19 02:15:24 PM
#1453   Securities Registration Statement (s-1) Source: Edgar (US Regulatory) Table of abracky 09/01/19 01:16:11 PM
#1452   WTF is this: Small Company Offering and Sale of abracky 08/30/19 12:14:07 PM
#1451   $2.05 stock1ace1 08/28/19 01:29:31 PM
#1450   1.96s up stock1ace1 08/28/19 11:14:39 AM
#1449   In 1.86 om bounce watch stock1ace1 08/28/19 09:41:43 AM
#1448   Current Report Filing (8-k) Source: Edgar (US Regulatory)   UNITED STATES S abracky 08/28/19 07:29:49 AM
#1447   Trovagene Presents Positive Clinical Data from Ongoing Phase MegaDeath 08/26/19 08:45:20 AM
#1446   Why are these fuckos selling shares at a bargain CyrusDaVirus 08/22/19 10:56:30 AM
#1445   Looking for us to hit $5 or $6 LoveItInBishop 08/19/19 11:12:48 PM
#1444   * * $TROV Video Chart 08-19-2019 * * ClayTrader 08/19/19 05:53:06 PM
#1443   The RSI is closed to 90 so expect CyrusDaVirus 08/19/19 04:06:30 PM
#1442   Boomage CyrusDaVirus 08/19/19 04:06:04 PM
#1441   Theres a lot of potential here with the CyrusDaVirus 08/19/19 12:47:36 PM
#1440   Bulls disagree.. hod test incoming stock1ace1 08/19/19 12:07:50 PM
#1439   Phase 2 data coming lol good call tho stock1ace1 08/19/19 11:13:18 AM
#1438   Time to start tanking, get out while you can. c-james08 08/19/19 11:03:01 AM
#1437   Boom 3$*+ stock1ace1 08/19/19 10:39:23 AM
#1436   Hod break incoming !! stock1ace1 08/19/19 10:37:54 AM
#1435   New data presentation on phase 2 coming Quote stock1ace1 08/19/19 10:37:29 AM
#1434   I got 1.70s happy w/ entry stock1ace1 08/19/19 10:36:13 AM
#1433   TROV - No brainer buy at $1.40 Chello 08/19/19 10:31:40 AM
#1432   3$ soon stock1ace1 08/19/19 09:33:15 AM
#1431   2.40s up stock1ace1 08/19/19 09:33:00 AM
#1430   Running today ! Volume.. stock1ace1 08/19/19 09:32:08 AM
#1429   2.30 p/m stock1ace1 08/19/19 08:30:47 AM
#1428   Real time over 2. abracky 08/16/19 04:00:10 PM
#1427   Hod break on watch ! stock1ace1 08/16/19 02:57:43 PM
#1426   2$ so close 1 hr left watch stock1ace1 08/16/19 02:57:12 PM
#1425   2$ soon stock1ace1 08/15/19 12:26:14 PM
#1424   News: $TROV Trovagene to Present New Data from whytestocks 08/15/19 11:10:27 AM
#1423   1.80$ break soon stock1ace1 08/15/19 10:51:23 AM
#1422   News out stock1ace1 08/15/19 10:41:26 AM
#1421   1.70s up running !!!! stock1ace1 08/15/19 10:41:04 AM
#1420   ESMO Accepts Trovagene AML Clinical Trial Abstract for abracky 07/22/19 10:36:22 AM
#1419   Trovagene Announces Initiation of Enrollment for Phase 1b/2 abracky 07/12/19 06:06:12 PM
#1418   TrovaGene Inc (NASDAQ:TROV) Short Interest Update Posted by Jeshia Costen on Jun abracky 06/26/19 11:12:42 AM
PostSubject